Nkcfo LLC Takes $606,000 Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Nkcfo LLC bought a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 30,000 shares of the company’s stock, valued at approximately $606,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Nisa Investment Advisors LLC raised its stake in shares of Hims & Hers Health by 679.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after acquiring an additional 1,603 shares during the period. Quest Partners LLC raised its position in Hims & Hers Health by 5,944.1% in the second quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after purchasing an additional 3,507 shares during the period. Van ECK Associates Corp purchased a new position in shares of Hims & Hers Health during the second quarter worth $111,000. Belpointe Asset Management LLC raised its holdings in shares of Hims & Hers Health by 10.0% in the 4th quarter. Belpointe Asset Management LLC now owns 13,238 shares of the company’s stock valued at $118,000 after buying an additional 1,205 shares during the period. Finally, Amalgamated Bank raised its holdings in shares of Hims & Hers Health by 55.9% in the 2nd quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock valued at $133,000 after buying an additional 2,354 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Wall Street Analysts Forecast Growth

HIMS has been the subject of several research reports. Deutsche Bank Aktiengesellschaft lifted their target price on Hims & Hers Health from $16.00 to $23.00 and gave the company a “hold” rating in a research report on Wednesday, August 7th. Needham & Company LLC assumed coverage on shares of Hims & Hers Health in a report on Thursday, August 22nd. They issued a “buy” rating and a $24.00 price objective for the company. Truist Financial upped their target price on shares of Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a research note on Thursday, July 18th. Piper Sandler reissued a “neutral” rating and issued a $18.00 price target on shares of Hims & Hers Health in a research report on Tuesday, August 6th. Finally, TD Cowen boosted their price target on shares of Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, July 11th. Eight investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $19.86.

Insider Activity

In related news, CEO Andrew Dudum sold 188,888 shares of Hims & Hers Health stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the sale, the chief executive officer now directly owns 33,502 shares in the company, valued at approximately $487,789.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other Hims & Hers Health news, CEO Andrew Dudum sold 188,888 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the transaction, the chief executive officer now owns 33,502 shares of the company’s stock, valued at $487,789.12. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Christiane Pendarvis sold 7,000 shares of Hims & Hers Health stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $15.15, for a total value of $106,050.00. Following the sale, the director now owns 23,917 shares in the company, valued at approximately $362,342.55. The disclosure for this sale can be found here. In the last quarter, insiders sold 701,904 shares of company stock worth $12,349,805. Corporate insiders own 17.71% of the company’s stock.

Hims & Hers Health Price Performance

Shares of NYSE HIMS opened at $16.29 on Friday. The business has a 50-day moving average of $17.35 and a two-hundred day moving average of $17.05. The company has a market capitalization of $3.50 billion, a price-to-earnings ratio of -1,628.50 and a beta of 1.05. Hims & Hers Health, Inc. has a 1 year low of $5.65 and a 1 year high of $25.74.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. Hims & Hers Health had a return on equity of 5.25% and a net margin of 1.70%. The firm had revenue of $315.65 million during the quarter, compared to the consensus estimate of $302.43 million. During the same period in the prior year, the company posted ($0.03) earnings per share. The firm’s quarterly revenue was up 51.8% compared to the same quarter last year. As a group, equities research analysts expect that Hims & Hers Health, Inc. will post 0.22 earnings per share for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.